Statistics for Cost utility analysis of long acting muscarinic antagonists (LAMAs) as an alternative to long acting beta agonists (labas) for treatment of severe COPD in the South African public sector

Total visits

views
Cost utility analysis of long acting muscarinic antagonists (LAMAs) as an alternative to long acting beta agonists (labas) for treatment of severe COPD in the South African public sector 24

Total visits per month

views
May 2024 0
June 2024 3
July 2024 1
August 2024 4
September 2024 2
October 2024 4
November 2024 0

File Visits

views
MPH_COMH7175A_1946476_03.06.2023.pdf 71

Top country views

views
South Africa 21
Tanzania 2
Norway 1

Top city views

views
Johannesburg 17
Dar es Salaam 2
Lenasia 2
Pretoria 1